Serum Institute of India (SII) has sought the DCGI's approval for market authorisation of its COVID-19 vaccine- Covovax- as a booster dose for those aged 18 years. The SII has sought clearance for the vaccine to be administered to adults who have been jabbed with two doses of Covishield or Covaxin, as per official sources.
It may be noted that Covovax is the indigenous version of a Covid vaccine developed by Novovax Inc and manufactured under a licence of the Serum Institute of India. In terms of formulation, it is a recombinant protein vaccine that uses spike proteins to familiarise the human body with how to develop immunity against SARS-CoV-
